7:00 | 30.08.2011
Business Wire News: Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer
Business Wire Pressemitteilung via mecom Mediensatellit /
Schlagwort(e): Sonderthemen
Business Wire News: Appointments to Ipsen’s Executive Committee:
Nathalie Joannes is nominated Executive Vice President, General
Counsel and Susheel Surpal is nominated Executive Vice President,
Chief Financial Officer
30.08.2011 / 07:00
———————————————————————
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN
DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
————————————————————————
PARIS –(BUSINESS WIRE)–30.08.2011–
Regulatory News:
Ipsen (Euronext : IPN ; ADR : IPSEY) today announced the appointment of two new
members to the Group’s Executive Committee: Nathalie Joannes, as Executive Vice
President, General Counsel, effective 1st of October 2011 and Susheel Surpal as
Executive Vice President, Chief Financial Officer, effective in the weeks to
come. With these two nominations, all the positions in the Group’s Executive
Committee have now been filled.
Nathalie Joannes, a Belgian national, is a member of the New York Bar, and a
graduate from the University of Pennsylvania Law School (Philadelphia – 1985)
and the University of Liege (Belgium – 1984). Since 2008, she served as Senior
Vice President and Chief European Counsel at Genzyme B.V. (Amsterdam). Nathalie
Joannes worked at Monsanto Company (St Louis, USA and Brussels, Belgium) from
1989 to 2001, notably as Assistant General Counsel in the United States. In
2001, Nathalie Joannes joined Serono International as Group General Counsel,
then Cardinal Health International (Switzerland) in 2007 where she served as
General Counsel, International.
Susheel Surpal, a British national, is a graduate from the Queen’s University
of Belfast (Ireland) and fellow of the Institute of Chartered Management
Accountants (FCMA – London). Since 2009, Susheel Surpal was member of the
Executive Committee and Financial Director of LABCO (European leader of medical
diagnostics). Throughout his career, Susheel Surpal served mainly as Financial
Director, from 1985 to 1994 at EDS, then at Sodexo as European Financial
Director, before his appointment as Corporate Controller (1999-2000), then
Corporate Controller and Senior Vice President at the BIC group. In 2003,
Susheel Surpal joined the BEL group as Corporate Financial Director.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding EUR1.1 billion in 2010. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by four franchises: neurology / Dysport^(R),
endocrinology / Somatuline^(R), uro-oncology / Decapeptyl^(R) and hemophilia.
Moreover, the Group has an active policy of partnerships. R&D is focused on
innovative and differentiated technological patient-driven platforms, peptides
and toxins. In 2010, R&D expenditure totaled more than EUR220 million, above 20%
of Group sales. The Group has total worldwide staff of close to 4,500
employees. Ipsen’s shares are traded on segment A of Euronext Paris (stock
code: IPN, ISIN code: FR0010259150) and eligible to the ‘Service de R?glement
Différé’ (’SRD’). The Group is part of the SBF 120 index. Ipsen has implemented
a Sponsored Level I American Depositary Receipt (ADR) program, which trade on
the over-the-counter market in the United States under the symbol IPSEY. For
more information on Ipsen, visit www.ipsen.com.
Ipsen’s Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are
based on the Group’s management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group’s future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Moreover,
the targets described in this document were prepared without taking into
account external growth assumptions and potential future acquisitions, which
may alter these parameters. These objectives are based on data and assumptions
regarded as reasonable by the Group. These targets depend on conditions or
facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising product
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. The Group must face or might face competition from
Generics that might translate into loose of market shares. Furthermore, the
Research and Development process involves several stages each of which involve
the substantial risk that the Group may fail to achieve its objectives and be
forced to abandon its efforts with regards to a product in which it has
invested significant sums. Therefore, the Group cannot be certain that
favourable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials
will be sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group’s
activities and financial results. The Group expressly disclaims any obligation
or undertaking to update or revise any forward looking statements, targets or
estimates contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements are
based, unless so required by applicable law. The Group’s business is subject to
the risk factors outlined in its registration documents filed with the French
Autorité des Marchés Financiers.
[CT]
Kontakt:
Ipsen
Media
Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com
or
Financial Community
Pierre Kemula
Investor Relations Officer
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
E-mail: pierre.kemula@ipsen.com
or
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
Ende der Pressemitteilung
———————————————————————
30.08.2011 Veröffentlichung einer Pressemitteilung, übermittelt durch
die DGAP – ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
http://www.dgap.de
———————————————————————
137400 30.08.2011
|
